Published in N Engl J Med on August 14, 2003
Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med (2008) 7.13
A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06
Pulmonary embolism in hospital practice. BMJ (2006) 2.27
Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ (2008) 2.02
Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med (2003) 2.00
Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis (2009) 1.71
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
Monitoring drug treatment. BMJ (2003) 1.44
Diagnosis and treatment of deep-vein thrombosis. CMAJ (2006) 1.44
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J (2011) 1.38
Splanchnic vein thrombosis in severe acute pancreatitis: a 2-year, single-institution experience. HPB (Oxford) (2011) 1.31
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ (2007) 1.29
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. Br J Clin Pharmacol (2012) 1.28
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol (2013) 1.17
Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood (2011) 1.14
Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thromb Haemost (2009) 1.09
Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J (2013) 1.05
Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging (2009) 1.04
Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr (2008) 1.03
EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study. J Gen Intern Med (2008) 1.03
Impact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy. Clin Med Res (2005) 0.99
Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost (2008) 0.99
Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96
Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96
Secondary prophylaxis with warfarin for venous thromboembolism. N Engl J Med (2003) 0.95
Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep (2013) 0.95
A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res (2011) 0.91
Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood (2014) 0.90
Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther Adv Drug Saf (2014) 0.89
Whole blood gene expression analyses in patients with single versus recurrent venous thromboembolism. Thromb Res (2011) 0.88
Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis (2013) 0.88
Predicting the risk of venous thromboembolism recurrence. Am J Hematol (2012) 0.88
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics (2014) 0.88
Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore) (2014) 0.86
Optimal duration of anticoagulation after venous thromboembolism. Circulation (2011) 0.85
Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation. Clinics (Sao Paulo) (2012) 0.84
[Thrombophilic and systemic risk factors in patients with retinal vein occlusion]. Ophthalmologe (2011) 0.84
Diagnosis and treatment of deep-vein thrombosis and approach to venous thromboembolism in obstetrics and gynecology. J Turk Ger Gynecol Assoc (2011) 0.83
Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review. Mayo Clin Proc (2011) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Low-intensity adjusted-dose warfarin for the prevention of hemodialysis catheter failure: a randomized, controlled trial. Clin J Am Soc Nephrol (2011) 0.83
Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol (2008) 0.82
Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thromb Res (2010) 0.82
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
Targeted gene sequencing identifies variants in the protein C and endothelial protein C receptor genes in patients with unprovoked venous thromboembolism. Arterioscler Thromb Vasc Biol (2013) 0.81
Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study. Thromb J (2005) 0.81
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol (2012) 0.79
Current strategies to minimize the bleeding risk of warfarin. J Blood Med (2013) 0.79
Venous thromboembolic prophylaxis for hip fractures. Osteoporos Int (2010) 0.78
Improving anticoagulation therapy using point-of-care testing and a standardized protocol. Ann Fam Med (2008) 0.78
Chronic thromboembolic pulmonary hypertension: Medical treatment. Pulm Circ (2013) 0.78
Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists. Medicine (Baltimore) (2015) 0.78
The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range? J Arthroplasty (2014) 0.77
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. Eur J Clin Pharmacol (2006) 0.77
Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol (2008) 0.77
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76
The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS One (2015) 0.76
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Anticoagulation in Heart Failure: a Review. J Atr Fibrillation (2015) 0.75
Duration of anticoagulation for venous thromboembolic events. Circulation (2014) 0.75
Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? PLoS One (2015) 0.75
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J (2016) 0.75
Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice. Medicine (Baltimore) (2015) 0.75
Spontaneous subscapular haematoma in a patient using warfarin therapy. BMJ Case Rep (2013) 0.75
Conventional-intensity was more effective than low-intensity warfarin therapy for preventing recurrent venous thromboembolism. ACP J Club (2004) 0.75
Long-term management of venous thromboembolism. Rev Cardiovasc Med (2004) 0.75
Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study). BMC Cardiovasc Disord (2013) 0.75
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep (2016) 0.75
Optimal duration of anticoagulation in patients with venous thromboembolism. Indian J Med Res (2011) 0.75
Stroke Prevention in Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism. N Engl J Med (2003) 0.75
Enzyme Polymorphism in Warfarin Dose Management After Pediatric Cardiac Surgery. Res Cardiovasc Med (2015) 0.75
Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur J Clin Pharmacol (2009) 0.75
Effect of a combined education and eHealth programme on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care. BMJ Open (2017) 0.75
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes. Intern Emerg Med (2017) 0.75
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med (2003) 8.33
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med (2015) 7.39
Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med (2003) 7.15
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med (2008) 6.00
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med (2008) 5.20
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med (2010) 4.63
Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol (2005) 4.45
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med (2003) 3.96
Do workplace health promotion (wellness) programs work? J Occup Environ Med (2014) 3.80
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med (2004) 3.74
Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ (2003) 3.73
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med (2007) 3.33
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med (2012) 3.16
Pulmonary embolism in pregnancy. Lancet (2009) 3.15
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007) 3.12
Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med (2010) 3.06
Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med (2007) 2.97
Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med (2004) 2.76
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol (2009) 2.58
Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol (2005) 2.53
Management of antiphospholipid antibody syndrome: a systematic review. JAMA (2006) 2.47
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood (2004) 2.41
Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med (2006) 2.40
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Advance targeted transfusion in anemic cardiac surgical patients for kidney protection: an unblinded randomized pilot clinical trial. Anesthesiology (2012) 2.29
Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26
Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest (2013) 2.24
Total knee arthroplasty in hemophilic arthropathy. J Bone Joint Surg Am (2002) 2.21
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med (2013) 2.21
Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med (2015) 2.16
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol (2010) 2.16
Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg (2003) 2.10
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J (2002) 2.09
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99
Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med (2011) 1.98
Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med (2008) 1.91